Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics announced on May 17, 2024, that it has granted option awards to Charles Huang, their new Director of Capital Markets and Investor Relations. The awards, given on May 8, 2024, include options to purchase up to 5,000 shares of Plus Therapeutics' common stock. These options will vest over four years, with one-fourth vesting after the first year and the remainder vesting monthly. The exercise price is set at the closing price on the grant date, May 8, 2024. This initiative aims to align the interests of Mr. Huang with the company’s shareholders. These awards were granted outside the 2020 Incentive Plan but follow similar terms.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on central nervous system cancers, announced its Q1 2024 financial results and business highlights.
The company closed a private placement financing for initial gross proceeds of $7.25 million, with a potential total of $19.25 million. Plus also received a $3 million award recommendation from the Department of Defense for its brain cancer program. Additionally, it acquired a diagnostic portfolio for leptomeningeal metastases and reported positive clinical trial data.
Financially, the company reported a decrease in operating loss to $3.3 million from $4.8 million in Q1 2023, and a net loss of $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, in the same period last year.
Upcoming milestones include several scientific presentations and potential FDA feedback on various clinical trials and applications.
Plus Therapeutics, Inc. will announce its first quarter 2024 financial results on May 15, 2024, after market close. The company is a clinical-stage pharmaceutical company focusing on developing targeted radiotherapeutics for central nervous system cancers. Plus Therapeutics' management team will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Plus Therapeutics, Inc. (Nasdaq: PSTV) acquired assets for the CNSide™ diagnostic platform to improve LM diagnosis accuracy. The company plans to develop the CNSide portfolio alongside the lead radiotherapeutic candidate and seek partnering opportunities. Topline data from the FORESEE trial met its primary endpoint, showing clinical utility in 40 patients. A full analysis is set for the SNO/ASCO Meeting in August 2024.
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host an investor call on May 9th, 2024, to discuss the acquisition of CNSide assets and provide updates on the FORESEE clinical trial. The company aims to leverage the acquired assets for CNS cancers and share key insights with investors.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced a private placement financing of up to $18 million, with $6.5 million in upfront gross proceeds and the potential for an additional $11.5 million in warrant exercise proceeds. The funding involves a securities purchase agreement with new institutional investors and Company insiders. The transaction, led by AIGH Capital Management , is expected to provide the company with an estimated $34 million cash runway to support corporate goals. The financing includes the issuance of common stock and accompanying warrants, with certain investors opting for pre-funded warrants. The private placement is set to close around May 8, 2024, with proceeds intended for general corporate purposes and funding the Re-SPECT LM clinical development program.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
